New peptide(s) derived from Epstein-Barr Virus receptor - of B lymphocytes and related antibodies, useful for treatment and diagnosis of e.g. lymphoma and EBV-related autoimmune disease

摘要

Peptides of formulae (I) and (II), and their functional equivs. differing by addn. deletion or modification of one or more amino acids, are new. LysHisArgGluArg AsnTyrTyrThr AspThrSerGlu LysGluAlaPheHis LeuGlnAlaArgGlu ValTyrSer ValAspProTyrAsnProAlaSer (I) HisLeuGluAlaArg GluValTyrSer ValAspProTyr AsnProAlaSer (II). (I) and (II) are derived from the intracellular C-terminus of the Epstein-Barr virus (EBV) receptor and of the C3d receptor (designated CR2). USE - (I) and (II) are used to modify growth of normal or EVA-transformed lymphocytes, e.g. to modulate proliferation of normal lymphocytes in cases of immune deficiency or of transformed cells in cases of leukaemia and lymphoma. Ab are used (1) to purify the proteins p68 (intracellular Ca binding protein) or P53 (an anti-oncogene protein), esp. by affinity chromatograph, (2) in diagnosis (esp. screening markers specific for evolution of transformed lymphocytic cells, including HIV-infected T cells, or monitoring EBV-related autoimmune diseases such as rheumatoid arthritis); or (3) therapeutically (e.g. to inhibit p53 in cases of Burkitt lymphoma or p68 in EBV-related autoimmune diseases) or for manipulating the idiotypic network.